Grown Rogue International (GRUSF) Return on Capital Employed (2011 - 2026)
Grown Rogue International's (GRUSF) quarterly Return on Capital Employed came in at 1559049040420.34% in Q1 2026, down 49923005.18% quarter-over-quarter from 3122900.78% in Q4 2025.
Grown Rogue International (GRUSF) Return on Capital Employed (2011 - 2026) Analysis & Trends
Grown Rogue International's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 1559049040420.34% for Q1 2026.
- On a quarterly basis, Return on Capital Employed changed N/A year-over-year to 1559049040420.34% in Q1 2026; TTM through Mar 2026 was 1559049040420.34%, a N/A change from a year earlier, with the FY2025 full-year figure at 1.22%, down 165.0% from the prior year.
- Return on Capital Employed slipped to 1559049040420.34% in Q1 2026 per GRUSF's latest filing, from 3122900.78% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 37.17% in Q1 2024 and bottomed at 1559049040420.34% in Q1 2026.
- The 4-year median for Return on Capital Employed is 962760.32% (2025), against an average of 194882214983.16%.
- Biggest YoY gain for Return on Capital Employed was 192555204 bps in 2025; the steepest drop was 363112499 bps in 2025.
- Year by year, Return on Capital Employed stood at 27.92% in 2023, then slumped by 44 bps to 15.7% in 2024, then slumped by 19894949 bps to 3122900.78% in 2025, then plunged by 49923005 bps to 1559049040420.34% in 2026.
- Per Business Quant, the three latest GRUSF Return on Capital Employed figures stand at 1559049040420.34% (Q1 2026), 3122900.78% (Q4 2025), and 1925536.34% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | -1,559,049,040,420.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,559,049,040,420.34% |
| Dec 31, 2025 | -3,122,900.78% |
| Sep 30, 2025 | -1,925,536.34% |
| Jun 30, 2025 | -3,631,106.79% |
| Sep 30, 2024 | 15.70% |
| Jun 30, 2024 | 18.20% |
| Mar 31, 2024 | 37.17% |
| Apr 30, 2023 | 27.92% |
| Apr 30, 2021 | -72.50% |
| Jan 31, 2021 | -13,809.96% |
| Oct 31, 2020 | -91.71% |
| Jul 31, 2020 | -30.46% |
| Jan 31, 2020 | 268.99% |
| Jan 31, 2019 | -162.65% |
| Oct 31, 2018 | 286.53% |
| Nov 30, 2017 | 41.96% |
| May 31, 2017 | -31.40% |
| Feb 28, 2017 | -49.53% |
| Nov 30, 2016 | -67.86% |
| Aug 31, 2013 | 1.53% |